Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.

Genta/Aventis Genasense appears to have a "real effect" on response rates in metastatic melanoma patients but not on progression-free survival or survival, FDA's Oncologic Drugs Advisory Committee concluded at its May 3 meeting